ArticleIntensive care medicine experimental2026
Continuous-flow ventilation with VENTIJET in moderate ARDS: a pilot safety and feasibility study.
Article in Intensive care medicine experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07121257 (Descriptive Analysis of the Functioning of the Ventijet Mechanical Ventilator During the COVID-19 Health Crisis in Patients With Acute Respiratory Failure), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Descriptive Analysis of the Functioning of the Ventijet Mechanical Ventilator During the COVID-19 Health Crisis in Patients With Acute Respiratory Failure
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute respiratory distress syndrome (ARDS) remains associated with high mortality and ventilator-induced lung injury. Continuous-flow ventilation (CFV) may reduce cyclic strain, but faced technical limitations. VENTIJET is a novel nozzle-based CFV ventilator designed for safe use in critically ill adults. This pilot study evaluated its feasibility and safety in patients with moderate ARDS.
methodsWe conducted a prospective, single-center pilot safety and feasibility study in intubated adults with moderate ARDS and stable oxygenation. After a 1-h baseline period with volume-controlled ventilation (Puritan Bennett™ 840), patients received up to 24 h of VENTIJET ventilation, then returned to conventional ventilation. Primary endpoints were feasibility and safety; secondary exploratory endpoints included gas exchange and respiratory mechanics.
resultsFourteen patients were enrolled. VENTIJET ventilation was successfully delivered in all participants without protocol interruptions or device-related serious adverse events. After 1 h, PaO₂/FiO₂ was 200 mm Hg compared to 192 mm Hg at baseline (p = 0.090). Over 24 h, oxygenation and respiratory system compliance showed modest improvement, with stable carbon dioxide (CO₂) elimination, transpulmonary pressures, and hemodynamics.
conclusionsIn patients with moderate ARDS, VENTIJET CFV was feasible and safe, maintaining stable gas exchange with modest improvements in respiratory mechanics. These findings support further evaluation in larger, controlled trials, including the full spectrum of ARDS. Trial registration ClinicalTrials.gov Identifier NCT07121257.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.